Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Feb;35(2):215–219. doi: 10.1128/aac.35.2.215

Screening and treatment of infections caused by resistant enterococci.

D J Herman 1, D N Gerding 1
PMCID: PMC244979  PMID: 2024952

Full text

PDF
217

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Basker M. J., Slocombe B., Sutherland R. Aminoglycoside-resistant enterococci. J Clin Pathol. 1977 Apr;30(4):375–380. doi: 10.1136/jcp.30.4.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beaty H. N., Turck M., Petersdorf R. G. Activity of broad-spectrum antibiotics against enterococci and their efficacy in enterococcal endocarditis. Ann N Y Acad Sci. 1967 Sep 27;145(2):464–472. doi: 10.1111/j.1749-6632.1967.tb50246.x. [DOI] [PubMed] [Google Scholar]
  3. Beaty H. N., Turck M., Petersdorf R. G. Ampicillin in the treatment of enterococcal endocarditis. Ann Intern Med. 1966 Oct;65(4):701–707. doi: 10.7326/0003-4819-65-4-701. [DOI] [PubMed] [Google Scholar]
  4. Bisno A. L., Dismukes W. E., Durack D. T., Kaplan E. L., Karchmer A. W., Kaye D., Rahimtoola S. H., Sande M. A., Sanford J. P., Watanakunakorn C. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA. 1989 Mar 10;261(10):1471–1477. [PubMed] [Google Scholar]
  5. Bush L. M., Boscia J. A., Kaye D. Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1988 Jun;32(6):877–881. doi: 10.1128/aac.32.6.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bush L. M., Calmon J., Cherney C. L., Wendeler M., Pitsakis P., Poupard J., Levison M. E., Johnson C. C. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med. 1989 Apr 1;110(7):515–520. doi: 10.7326/0003-4819-110-7-515. [DOI] [PubMed] [Google Scholar]
  7. Cook F. V., Coddington C. C., Wadland W. C., Farrar W. E., Jr Treatment of bacterial endocarditis with vancomycin. Am J Med Sci. 1978 Sep-Oct;276(2):153–158. doi: 10.1097/00000441-197809000-00002. [DOI] [PubMed] [Google Scholar]
  8. Courvalin P., Carlier C., Collatz E. Plasmid-mediated resistance to aminocyclitol antibiotics in group D streptococci. J Bacteriol. 1980 Aug;143(2):541–551. doi: 10.1128/jb.143.2.541-551.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. D'Amato R. F., Mathew A., Hochstein L., Cleri D. J., Johnson J. In vitro activity of ampicillin/sulbactam against enterococci determined by the time-kill method. Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):9–11. doi: 10.1016/0732-8893(89)90037-0. [DOI] [PubMed] [Google Scholar]
  10. Dickinson G., Rodriguez K., Arcey S., Alea A., Greenman R. Efficacy of imipenem/cilastatin in endocarditis. Am J Med. 1985 Jun 7;78(6A):117–121. doi: 10.1016/0002-9343(85)90113-5. [DOI] [PubMed] [Google Scholar]
  11. Eliopoulos G. M., Eliopoulos C. T. Therapy of enterococcal infections. Eur J Clin Microbiol Infect Dis. 1990 Feb;9(2):118–126. doi: 10.1007/BF01963636. [DOI] [PubMed] [Google Scholar]
  12. Eliopoulos G. M., Farber B. F., Murray B. E., Wennersten C., Moellering R. C., Jr Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother. 1984 Mar;25(3):398–399. doi: 10.1128/aac.25.3.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Eliopoulos G. M., Moellering R. C., Jr Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother. 1981 May;19(5):789–793. doi: 10.1128/aac.19.5.789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Farber B. F., Moellering R. C., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. doi: 10.1128/aac.23.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fernandez-Guerrero M., Rouse M. S., Henry N. K., Geraci J. E., Wilson W. R. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother. 1987 Mar;31(3):430–433. doi: 10.1128/aac.31.3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fernández-Guerrero M. L., Barros C., Rodriguez Tudela J. L., Fernández Roblas R., Soriano F. Aortic endocarditis caused by gentamicin-resistant Enterococcus faecalis. Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):525–527. doi: 10.1007/BF01962605. [DOI] [PubMed] [Google Scholar]
  17. Friedberg C. K., Rosen K. M., Bienstock P. A. Vancomycin therapy for enterococcal and Streptococcus viridans endocarditis. Successful treatment of six patients. Arch Intern Med. 1968 Aug;122(2):134–140. [PubMed] [Google Scholar]
  18. Fuursted K. Comparative killing activity and postantibiotic effect of streptomycin combined with ampicillin, ciprofloxacin, imipenem, piperacillin or vancomycin against strains of Streptococcus faecalis and Streptococcus faecium. Chemotherapy. 1988;34(3):229–234. doi: 10.1159/000238574. [DOI] [PubMed] [Google Scholar]
  19. GERACI J. E., MARTIN W. J. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases. Circulation. 1954 Aug;10(2):173–194. doi: 10.1161/01.cir.10.2.173. [DOI] [PubMed] [Google Scholar]
  20. Goodhart G. L. In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA. 1984 Nov 16;252(19):2748–2749. [PubMed] [Google Scholar]
  21. Hamilton-Miller J. M. Antibiotic treatment of enterococcal infection. Antimicrob Agents Chemother. 1989 Jun;33(6):989–989. doi: 10.1128/aac.33.6.989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hartzen S. H., Frimodt-Möller N., Andreasen J. J. In vitro antibacterial activities of eleven antibiotics against S. faecalis. APMIS. 1988 Jul;96(7):584–588. [PubMed] [Google Scholar]
  23. Henry N. K., Wilson W. R., Geraci J. E. Treatment of streptomycin-susceptible enterococcal experimental endocarditis with combinations of penicillin and low- or high-dose streptomycin. Antimicrob Agents Chemother. 1986 Nov;30(5):725–728. doi: 10.1128/aac.30.5.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hindes R. G., Willey S. H., Eliopoulos G. M., Rice L. B., Eliopoulos C. T., Murray B. E., Moellering R. C., Jr Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1989 Jul;33(7):1019–1022. doi: 10.1128/aac.33.7.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hook E. W., 3rd, Johnson W. D., Jr Vancomycin therapy of bacterial endocarditis. Am J Med. 1978 Sep;65(3):411–415. doi: 10.1016/0002-9343(78)90766-0. [DOI] [PubMed] [Google Scholar]
  26. Hook E. W., 3rd, Roberts R. B., Sande M. A. Antimicrobial therapy of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1975 Nov;8(5):564–570. doi: 10.1128/aac.8.5.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ikeda D. P., Barry A. L., Andersen S. G. Emergence of Streptococcus faecalis isolates with high-level resistance to multiple aminocyclitol aminoglycosides. Diagn Microbiol Infect Dis. 1984 Jun;2(3):171–177. doi: 10.1016/0732-8893(84)90027-0. [DOI] [PubMed] [Google Scholar]
  28. Indrelie J. A., Wilson W. R., Matsumoto J. Y., Geraci J. E., Washington J. A., 2nd Synergy of imipenem or penicillin G and aminoglycosides against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother. 1984 Dec;26(6):909–912. doi: 10.1128/aac.26.6.909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ingerman M., Pitsakis P. G., Rosenberg A., Hessen M. T., Abrutyn E., Murray B. E., Levison M. E. beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis. 1987 Jun;155(6):1226–1232. doi: 10.1093/infdis/155.6.1226. [DOI] [PubMed] [Google Scholar]
  30. Kaye D. Enterococci. Biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med. 1982 Oct 25;142(11):2006–2009. doi: 10.1001/archinte.142.11.2006. [DOI] [PubMed] [Google Scholar]
  31. Kim M. J., Weiser M., Gottschall S., Randall E. L. Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agents. J Clin Microbiol. 1987 May;25(5):787–790. doi: 10.1128/jcm.25.5.787-790.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Krogstad D. J., Korfhagen T. R., Moellering R. C., Jr, Wennersten C., Swartz M. N. Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest. 1978 Aug;62(2):480–486. doi: 10.1172/JCI109149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Leport C., Perronne C., Massip P., Canton P., Leclercq P., Bernard E., Lutun P., Garaud J. J., Vilde J. L. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother. 1989 Jun;33(6):871–876. doi: 10.1128/aac.33.6.871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lipman M. L., Silva J., Jr Endocarditis due to Streptococcus faecalis with high-level resistance to gentamicin. Rev Infect Dis. 1989 Mar-Apr;11(2):325–328. doi: 10.1093/clinids/11.2.325. [DOI] [PubMed] [Google Scholar]
  35. Mackowiak P. A. The enterococci: evidence of species-specific clinical and microbiologic heterogeneity. Am J Med Sci. 1989 Apr;297(4):238–243. doi: 10.1097/00000441-198904000-00008. [DOI] [PubMed] [Google Scholar]
  36. Mandell G. L., Kaye D., Levison M. E., Hook E. W. Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med. 1970 Feb;125(2):258–264. doi: 10.1001/archinte.125.2.258. [DOI] [PubMed] [Google Scholar]
  37. Mandell G. L., Lindsey E., Hook E. W. Synergism of vancomycin and streptomycin for enterococci. Am J Med Sci. 1970 May;259(5):346–349. doi: 10.1097/00000441-197005000-00006. [DOI] [PubMed] [Google Scholar]
  38. Martino P., Venditti M., Micozzi A., Brandimarte C., Gentile G., Santini C., Serra P. Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother. 1989 Aug;33(8):1329–1334. doi: 10.1128/aac.33.8.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Matsumoto J. Y., Wilson W. R., Wright A. J., Geraci J. E., Washington J. A., 2nd Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob Agents Chemother. 1980 Dec;18(6):944–947. doi: 10.1128/aac.18.6.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Moellering R. C., Jr, Korzeniowski O. M., Sande M. A., Wennersten C. B. Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis. 1979 Aug;140(2):203–208. doi: 10.1093/infdis/140.2.203. [DOI] [PubMed] [Google Scholar]
  41. Moellering R. C., Jr, Watson B. K., Kunz L. J. Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med. 1974 Aug;57(2):239–250. doi: 10.1016/0002-9343(74)90448-3. [DOI] [PubMed] [Google Scholar]
  42. Moellering R. C., Jr, Wennersten C. Therapeutic potential of rifampin in enterococcal infections. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S528–S532. doi: 10.1093/clinids/5.supplement_3.s528. [DOI] [PubMed] [Google Scholar]
  43. Moody J. A., Peterson L. R., Gerding D. N. In vitro activity of ciprofloxacin combined with azlocillin. Antimicrob Agents Chemother. 1985 Dec;28(6):849–850. doi: 10.1128/aac.28.6.849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Murray B. E. Antibiotic treatment of enterococcal infections. Antimicrob Agents Chemother. 1989 Aug;33(8):1411–1411. doi: 10.1128/aac.33.8.1411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Murray B. E. The life and times of the Enterococcus. Clin Microbiol Rev. 1990 Jan;3(1):46–65. doi: 10.1128/cmr.3.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Nachamkin I., Axelrod P., Talbot G. H., Fischer S. H., Wennersten C. B., Moellering R. C., Jr, MacGregor R. R. Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol. 1988 Jul;26(7):1287–1291. doi: 10.1128/jcm.26.7.1287-1291.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Neu H. C. Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1025–S1035. doi: 10.1093/clinids/11.supplement_5.s1025. [DOI] [PubMed] [Google Scholar]
  48. Nicas T. I., Cole C. T., Preston D. A., Schabel A. A., Nagarajan R. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother. 1989 Sep;33(9):1477–1481. doi: 10.1128/aac.33.9.1477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Patterson J. E., Colodny S. M., Zervos M. J. Serious infection due to beta-lactamase-producing Streptococcus faecalis with high-level resistance to gentamicin. J Infect Dis. 1988 Nov;158(5):1144–1145. doi: 10.1093/infdis/158.5.1144. [DOI] [PubMed] [Google Scholar]
  50. Patterson J. E., Masecar B. L., Zervos M. J. Characterization and comparison of two penicillinase-producing strains of Streptococcus (Enterococcus) faecalis. Antimicrob Agents Chemother. 1988 Jan;32(1):122–124. doi: 10.1128/aac.32.1.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Peterson L. R., Moody J. A., Fasching C. E., Gerding D. N. In vivo and in vitro activity of ciprofloxacin plus azlocillin against 12 streptococcal isolates in a neutropenic site model. Diagn Microbiol Infect Dis. 1987 Jun;7(2):127–136. doi: 10.1016/0732-8893(87)90030-7. [DOI] [PubMed] [Google Scholar]
  52. Rice L. B., Eliopoulos G. M., Moellering R. C., Jr In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother. 1989 Apr;33(4):470–473. doi: 10.1128/aac.33.4.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Ruhen R. W., Darrell J. H. Antibiotic synergism against group D streptococci in the treatment of endocarditis. Med J Aust. 1973 Jul 21;2(3):114–116. doi: 10.5694/j.1326-5377.1973.tb128693.x. [DOI] [PubMed] [Google Scholar]
  54. Ryan R. W., Kwasnik I., Tilton R. C. Methodological variation in antibiotic synergy tests against enterococci. J Clin Microbiol. 1981 Jan;13(1):73–75. doi: 10.1128/jcm.13.1.73-75.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Sahm D. F., Kissinger J., Gilmore M. S., Murray P. R., Mulder R., Solliday J., Clarke B. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 1989 Sep;33(9):1588–1591. doi: 10.1128/aac.33.9.1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Sahm D. F., Koburov G. T. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother. 1989 Jan;33(1):71–77. doi: 10.1128/aac.33.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Sahm D. F., Torres C. Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis. J Clin Microbiol. 1988 Feb;26(2):250–256. doi: 10.1128/jcm.26.2.250-256.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sahm D. F., Torres C. High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis. J Clin Microbiol. 1988 Feb;26(2):257–260. doi: 10.1128/jcm.26.2.257-260.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Scheld W. M., Keeley J. M. Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):65–78. doi: 10.1093/jac/12.suppl_d.65. [DOI] [PubMed] [Google Scholar]
  60. Smith S. M., Eng R. H. Interaction of ciprofloxacin with ampicillin and vancomycin for Streptococcus faecalis. Diagn Microbiol Infect Dis. 1988 Apr;9(4):239–243. doi: 10.1016/0732-8893(88)90115-0. [DOI] [PubMed] [Google Scholar]
  61. Spiegel C. A., Huycke M. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance. Arch Intern Med. 1989 Aug;149(8):1873–1875. [PubMed] [Google Scholar]
  62. Standiford H. D., De Maine J. B., Kirby W. M. Antibiotic synergism of enterococci. Relation to inhibitory concentrations. Arch Intern Med. 1970 Aug;126(2):255–259. [PubMed] [Google Scholar]
  63. Sullam P. M., Täuber M. G., Hackbarth C. J., Sande M. A. Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1985 Jan;27(1):135–136. doi: 10.1128/aac.27.1.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Thauvin C., Eliopoulos G. M., Willey S., Wennersten C., Moellering R. C., Jr Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb;31(2):139–143. doi: 10.1128/aac.31.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Webster A., Wilson A. P., Williams A. H., Treasure T., Grüneberg R. N. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis. Postgrad Med J. 1987 Aug;63(742):621–624. doi: 10.1136/pgmj.63.742.621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Williamson R., Gutmann L., Horaud T., Delbos F., Acar J. F. Use of penicillin-binding proteins for the identification of enterococci. J Gen Microbiol. 1986 Jul;132(7):1929–1937. doi: 10.1099/00221287-132-7-1929. [DOI] [PubMed] [Google Scholar]
  67. Wilson W. R., Wilkowske C. J., Wright A. J., Sande M. A., Geraci J. E. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med. 1984 Jun;100(6):816–823. doi: 10.7326/0003-4819-100-6-816. [DOI] [PubMed] [Google Scholar]
  68. Wright A. J., Wilson W. R., Matsumoto J. Y., Washington J. A., 2nd, Geraci J. E. Influence of gentamicin dose size on the efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. Antimicrob Agents Chemother. 1982 Dec;22(6):972–975. doi: 10.1128/aac.22.6.972. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES